Medifast (NYSE:MED) Director Parsa Kiai Purchases 29,337 Shares

Medifast Inc (NYSE:MED) Director Parsa Kiai purchased 29,337 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were purchased at an average cost of $11.66 per share, with a total value of $342,069.42. Following the completion of the purchase, the director owned 619,331 shares in the company, valued at $7,221,399.46. This represents a 4.97% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Parsa Kiai also recently made the following trade(s):

• On Thursday, August 20th, Parsa Kiai acquired 43,150 shares of Medifast stock. The stock was purchased at an average cost of $11.60 per share, for a total transaction of $500,540.00.

Medifast Stock Up 3.3%

Shares of Medifast stock opened at $12.00 on Friday. The firm has a market cap of $134.17 million, a price-to-earnings ratio of -5.15 and a beta of 0.65. The business has a fifty day simple moving average of $10.92 and a 200-day simple moving average of $11.06. Medifast Inc has a fifty-two week low of $9.22 and a fifty-two week high of $14.67.

Medifast (NYSE:MED) last released its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.The firm had revenue of $76.38 million for the quarter, compared to analyst estimates of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Analysts anticipate that Medifast Inc will post -1 earnings per share for the current fiscal year.

Institutional Trading of Medifast

Several large investors have recently added to or reduced their stakes in the company. Ancora Advisors LLC purchased a new position in shares of Medifast during the second quarter valued at $75,000. Empowered Funds LLC purchased a new stake in Medifast in the 2nd quarter worth about $701,000. Bank of America Corp DE purchased a new stake in Medifast in the 2nd quarter worth about $924,000. PDT Partners LLC acquired a new stake in Medifast during the 2nd quarter worth about $348,000. Finally, Ieq Capital LLC acquired a new stake in Medifast during the 2nd quarter worth about $114,000. 95.51% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Weiss Ratings upgraded shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday. Zacks Research lowered Medifast from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Medifast presently has a consensus rating of “Reduce” and an average price target of $12.00.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.